423 related articles for article (PubMed ID: 14662882)
21. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
Quinn KM; Da Costa A; Yamamoto A; Berry D; Lindsay RW; Darrah PA; Wang L; Cheng C; Kong WP; Gall JG; Nicosia A; Folgori A; Colloca S; Cortese R; Gostick E; Price DA; Gomez CE; Esteban M; Wyatt LS; Moss B; Morgan C; Roederer M; Bailer RT; Nabel GJ; Koup RA; Seder RA
J Immunol; 2013 Mar; 190(6):2720-35. PubMed ID: 23390298
[TBL] [Abstract][Full Text] [Related]
23. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
24. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines.
Singh RA; Barry MA
J Immunol; 2004 Oct; 173(7):4387-93. PubMed ID: 15383568
[TBL] [Abstract][Full Text] [Related]
25. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
Andersson AC; Holst PJ
J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
[TBL] [Abstract][Full Text] [Related]
26. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
27. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
28. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.
Martins MA; Bonaldo MC; Rudersdorf RA; Piaskowski SM; Rakasz EG; Weisgrau KL; Furlott JR; Eernisse CM; Veloso de Santana MG; Hidalgo B; Friedrich TC; Chiuchiolo MJ; Parks CL; Wilson NA; Allison DB; Galler R; Watkins DI
PLoS One; 2013; 8(1):e54434. PubMed ID: 23336000
[TBL] [Abstract][Full Text] [Related]
30. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens.
Friedman RS; Frankel FR; Xu Z; Lieberman J
J Virol; 2000 Nov; 74(21):9987-93. PubMed ID: 11024127
[TBL] [Abstract][Full Text] [Related]
31. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
32. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
33. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
[TBL] [Abstract][Full Text] [Related]
34. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.
Lin SW; Hensley SE; Tatsis N; Lasaro MO; Ertl HC
J Clin Invest; 2007 Dec; 117(12):3958-70. PubMed ID: 18008010
[TBL] [Abstract][Full Text] [Related]
35. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
36. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
37. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.
Roshorm Y; Cottingham MG; Potash MJ; Volsky DJ; Hanke T
Eur J Immunol; 2012 Dec; 42(12):3243-55. PubMed ID: 22930183
[TBL] [Abstract][Full Text] [Related]
38. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.
Small JC; Haut LH; Bian A; Ertl HC
J Leukoc Biol; 2014 Nov; 96(5):821-31. PubMed ID: 25082150
[TBL] [Abstract][Full Text] [Related]
39. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
40. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Lévy Y; Lacabaratz C; Ellefsen-Lavoie K; Stöhr W; Lelièvre JD; Bart PA; Launay O; Weber J; Salzberger B; Wiedemann A; Surenaud M; Koelle DM; Wolf H; Wagner R; Rieux V; Montefiori DC; Yates NL; Tomaras GD; Gottardo R; Mayer B; Ding S; Thiébaut R; McCormack S; Chêne G; Pantaleo G
PLoS Pathog; 2020 Jun; 16(6):e1008522. PubMed ID: 32589686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
